Relay Therapeutics
RLAY
157 hedge funds and large institutions have $2.16B invested in Relay Therapeutics in 2023 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 50 increasing their positions, 50 reducing their positions, and 32 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
18% more call options, than puts
Call options by funds: $5.12M | Put options by funds: $4.35M
14% more capital invested
Capital invested by funds: $1.9B → $2.16B (+$258M)
2% more ownership
Funds ownership: 105.95% → 107.95% (+2%)
0% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 50
5% less funds holding
Funds holding: 165 → 157 (-8)
22% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 32
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
+$47.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$42.5M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$22M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$11.8M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$5.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$32.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.6M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$13.5M |
| 4 |
Millennium Management
New York
|
-$10.3M |
| 5 |
State Street
Boston,
Massachusetts
|
-$6.89M |
RLAY Hedge Fund Activity: Q1 2023 in Review
157 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Relay Therapeutics (RLAY) for Q1 2023, worth a combined $2.16B — up 14% from $1.9B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of RLAY and 25 opened new positions — a net loss of 7 holders — while 50 trimmed existing stakes and 50 added.
The largest buyer was Casdin Capital, adding an estimated $47.8M. The largest seller was Morgan Stanley, cutting an estimated $32.4M.
- 157 institutional investors held Relay Therapeutics (RLAY) as of Q1 2023, down from 165 in Q4 2022.
- Funds reported $2.16B of Relay Therapeutics stock for Q1 2023, up 14% quarter-over-quarter.
- 25 funds opened new Relay Therapeutics positions in Q1 2023 and 32 closed out, a net change of -7 holders.
- The largest Relay Therapeutics buyer in Q1 2023 was Casdin Capital, an estimated $47.8M added.
- The largest Relay Therapeutics seller in Q1 2023 was Morgan Stanley, an estimated $32.4M sold.
Based on aggregated 13F filings for Q1 2023.